Shares of Becton Dickinson have dropped over 10% since hitting a record high in early August. Kevin Walkush, portfolio manager for the Jensen Quality Growth Fund (JENSX), said the syringe-maker’s investors won’t feel the pinch much longer. ‘There is a little bit of a break in health care right now and they sort of got caught in the downdraft,’ said Walkush. ‘But we think fundamentals are preserved and we think the company has a very good long term opportunity.’ Shares of Becton Dickinson have only dropped 2% thus far this year despite the steep selloff of late. The Jensen Quality Growth Fund is down almost 2% this year, according to fund-tracker Morningstar. The S&P 500 index has fallen over 3%. Walkush is also positive on Accenture’s (ACN) stock, which is up over 15% year-to-date. In this case, he said the uncertainty in the global economy is actually a boon for the consultant. ‘Usually when things get a little bit rough companies want to figure out how to get better,’ said Walkush. ‘As the world’s largest business services company, they will benefit from that demand.’ Meanwhile, shares of Microsoft (MSFT) are up almost 1% so far in 2015 and have been unable to breach the $50 per share mark. Walkush said the technology giant will soon crash through that ceiling as the leadership change to Satya Nadella has been paying off in spades.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
